RegulatoryOfficial

FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease

🇺🇸 FDA · Wed 18 Nov 2026

The US regulator has cleared Sanofi unit Genzyme's venglustat tablets for adults and children weighing at least 15 kg, with psychiatric risks highlighted in the safety information.

The US Food and Drug Administration approved Infilbray (venglustat) tablets on 18 November 2026 as the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3). The indication covers adults and paediatric patients weighing at least 15 kg, roughly 33 pounds. The marketing authorisation was granted to Genzyme Corporation, a Sanofi company.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.